NASDAQ:STOK

Stoke Therapeutics Stock Insider Trading

etoro logo Buy STOK
*Your capital is at risk
$29.46
+0.780 (+2.72%)
At Close: Jun 03, 2026

Stoke Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -9.25. In total, the insiders bought 1.18M and sold 143.12K STOK shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
-9.25
Buy 1.18M shares
Sell 143.12K shares
47% Buy Activity
Negligible or No Correlation
Buy Signal Low Confidence
Feb 17, 2026

Analysis Breakdown:

  • Weakened by a contradictory negative Insider Power Score.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Mar 13, 2026
Sell
Common Stock
S-Sale
Levin Arthur A
Director
Director 605
Value: $22.3K
Mar 10, 2026
Buy
Stock Option (Right to Buy)
M-Exempt
Tzianabos Arthur
Interim Executive Chair
Officer 3 955
Value: $32.9K
Mar 10, 2026
Buy
Common Stock
M-Exempt
Tzianabos Arthur
Interim Executive Chair
Officer 3 955
Value: $32.9K
Mar 10, 2026
Sell
Common Stock
S-Sale
Tzianabos Arthur
Interim Executive Chair
Officer 4 355
Value: $174.2K
Mar 10, 2026
Sell
Common Stock
S-Sale
Krainer Adrian R.
Director
Director 33 243
Value: $1.32M
Mar 02, 2026
Sell
Common Stock
S-Sale
Krainer Adrian R.
Director
Director 7 229
Value: $286.7K
Feb 17, 2026
Buy
Restricted Stock Units
A-Award
Allan Jonathan
General Counsel & Corp Sec
Officer 35 000
Value: $1.09M
Feb 17, 2026
Buy
Employee Stock Option (Right to Buy)
A-Award
Allan Jonathan
General Counsel & Corp Sec
Officer 53 000
Value: $1.65M
Feb 17, 2026
Buy
Restricted Stock Units
A-Award
Hoitt Jason
Chief Patient Officer
Officer 48 000
Value: $1.49M
Feb 17, 2026
Buy
Employee Stock Option (Right to Buy)
A-Award
Hoitt Jason
Chief Patient Officer
Officer 72 000
Value: $2.24M
Feb 17, 2026
Buy
Restricted Stock Units
A-Award
Leggett Thomas
Chief Financial Officer
C-Suite Officer 40 000
Value: $1.24M
Feb 17, 2026
Buy
Employee Stock Option (Right to Buy)
A-Award
Leggett Thomas
Chief Financial Officer
C-Suite Officer 60 000
Value: $1.87M
Feb 17, 2026
Buy
Restricted Stock Units
A-Award
Smith Ian F
Chief Executive Officer
CEO / President 129 000
Value: $4.01M
Feb 17, 2026
Buy
Employee Stock Option (Right to Buy)
A-Award
Smith Ian F
Chief Executive Officer
CEO / President 193 000
Value: $6.00M
Feb 17, 2026
Buy
Restricted Stock Units
A-Award
Ticho Barry
Chief Medical Officer
Officer 40 000
Value: $1.24M
Feb 17, 2026
Buy
Employee Stock Option (Right to Buy)
A-Award
Ticho Barry
Chief Medical Officer
Officer 60 000
Value: $1.87M
Dec 31, 2025
Buy
Restricted Stock Units
M-Exempt
Levin Arthur A
Director
Director 1 211
Value: $38.4K
Dec 31, 2025
Buy
Common Stock
M-Exempt
Levin Arthur A
Director
Director 1 211
Value: $38.4K
Dec 08, 2025
Sell
Common Stock
S-Sale
Kaye Edward M. Md
Director
Director 3 825
Value: $120.3K
Dec 08, 2025
Sell
Common Stock
S-Sale
Allan Jonathan
General Counsel & Corp Sec
Officer 2 678
Value: $87.3K
Dec 08, 2025
Sell
Common Stock
S-Sale
Allan Jonathan
General Counsel & Corp Sec
Officer 1 300
Value: $41.1K
Dec 08, 2025
Sell
Common Stock
S-Sale
Kaye Edward M. Md
Director
Director 8 274
Value: $269.1K
Dec 08, 2025
Sell
Common Stock
S-Sale
Kaye Edward M. Md
Director
Director 1 331
Value: $44.1K
Dec 05, 2025
Sell
Common Stock
S-Sale
Kaye Edward M. Md
Director
Director 1 681
Value: $52.4K
Dec 05, 2025
Sell
Common Stock
S-Sale
Kaye Edward M. Md
Director
Director 6 367
Value: $199.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT STOKE THERAPEUTICS, INC.
Stoke Therapeutics
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome,...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE